Form 4: Alkermes Executive Gaffin Executes Stock Sale

David Joseph Gaffin, EVP and CLO of Alkermes plc, sold 2,034 ordinary shares as part of a pre-arranged 10b5-1 trading plan.

Summary

• David Joseph Gaffin, EVP and CLO of Alkermes, Inc., sold 2,034 ordinary shares of Alkermes plc (ALKS).
• The shares were sold at a price of $43.05 per share.
• Following the transaction, the reporting person retains beneficial ownership of 229,524 ordinary shares.
• The transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 19, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was pre-planned and represents a small fraction of the executive's total holdings.

Positives

• The sale was conducted under a pre-established Rule 10b5-1 trading plan, which is a standard mechanism for executives to sell shares without triggering insider trading concerns.

Negatives

• The transaction represents a reduction in the executive's direct equity stake in the company.

Risks

• None identified beyond standard market volatility associated with equity holdings.

Future Outlook

No specific forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is common in the biotechnology sector and generally does not signal a lack of confidence in company performance.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate officers to manage personal liquidity while maintaining regulatory compliance.

Stakeholder Impact

• Minimal impact on shareholders as the sale was executed through a pre-planned, non-discretionary trading program.

Next Steps

• No future actions or milestones mentioned.

Key Dates

Keywords

Alkermes, ALKS, Insider Trading, Form 4, Executive Compensation, Biotech